Clinical Trial Update: A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE) [Phase 3]

View source ↗

Summary

The BRAVE Phase 3 trial is recruiting to evaluate omaveloxolone (BIIB141) for Friedreich's ataxia in children aged 2 to 15 and assess long-term safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• BIIB141 (Omaveloxolone) (Omaveloxolone)

Snippet

Sponsor: Biogen | Conditions: Friedreich Ataxia | Phase 3 | Status: RECRUITING